Grifols SA
Open
$8.20
Prev. Close
$8.20
High
$8.20
Low
$8.20
Market Snapshot
0.44
$29.49B
Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
emptyResult
Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Recently from Cashu
Grifols SA: Leading Innovations in Plasma-Derived Therapies and Biosimilars for Future Growth
Grifols SA: Navigating the Future of Plasma-Derived Therapies Grifols SA stands at a pivotal moment in the biopharmaceutical industry, particularly in the realm of plasma-derived therapies. As a leadi…
Grifols SA Under Governance Scrutiny: Mason Capital Raises Transparency Concerns
Grifols Faces Governance Scrutiny Amid Transparency Concerns Mason Capital Management LLC has raised significant concerns about the governance practices at Grifols S.A., particularly regarding the com…
Grifols SA Governance Under Scrutiny: Mason Capital Demands Transparency from Board Member
Grifols Faces Governance Scrutiny Amid Calls for Transparency In a recent development, Mason Capital Management LLC, which manages funds holding approximately 2.1% of Grifols S.A. class A shares, has…
Grifols SA Under Governance Scrutiny as Mason Capital Demands Board Transparency
Grifols Faces Governance Scrutiny Amidst Calls for Board Transparency Mason Capital Management LLC, which controls approximately 2.1% of Grifols S.A. class A shares, recently addresses the Grifols Boa…